β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares
- PMID: 28249154
- PMCID: PMC5527297
- DOI: 10.1016/j.celrep.2017.02.004
β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares
Abstract
Aging and lipotoxicity are two major risk factors for gout that are linked by the activation of the NLRP3 inflammasome. Neutrophil-mediated production of interleukin-1β (IL-1β) drives gouty flares that cause joint destruction, intense pain, and fever. However, metabolites that impact neutrophil inflammasome remain unknown. Here, we identified that ketogenic diet (KD) increases β-hydroxybutyrate (BHB) and alleviates urate crystal-induced gout without impairing immune defense against bacterial infection. BHB inhibited NLRP3 inflammasome in S100A9 fibril-primed and urate crystal-activated macrophages, which serve to recruit inflammatory neutrophils in joints. Consistent with reduced gouty flares in rats fed a ketogenic diet, BHB blocked IL-1β in neutrophils in a NLRP3-dependent manner in mice and humans irrespective of age. Mechanistically, BHB inhibited the NLRP3 inflammasome in neutrophils by reducing priming and assembly steps. Collectively, our studies show that BHB, a known alternate metabolic fuel, is also an anti-inflammatory molecule that may serve as a treatment for gout.
Keywords: IL-1; NLRP3 inflammasome; aging; gout; inflammation; neutrophil; β-hydroxybutyrate.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
Figures
References
-
- Cahill GF., Jr Fuel metabolism in starvation. Annual review of nutrition. 2006;26:1–22. - PubMed
-
- Cassel SL, Janczy JR, Bing X, Wilson SP, Olivier AK, Otero JE, Iwakura Y, Shayakhmetov DM, Bassuk AG, Abu-Amer Y, et al. Inflammasome-independent IL-1beta mediates autoinflammatory disease in Pstpip2-deficient mice. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:1072–1077. - PMC - PubMed
-
- Clarke K, Tchabanenko K, Pawlosky R, Carter E, Todd King M, Musa-Veloso K, Ho M, Roberts A, Robertson J, Vanitallie TB, et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regulatory toxicology and pharmacology: RTP. 2012;63:401–408. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HHMI/Howard Hughes Medical Institute/United States
- P30 DK045735/DK/NIDDK NIH HHS/United States
- R01 AI105097/AI/NIAID NIH HHS/United States
- R01 DK101984/DK/NIDDK NIH HHS/United States
- R01 AR070811/AR/NIAMS NIH HHS/United States
- P01 AG051459/AG/NIA NIH HHS/United States
- T32 AI007019/AI/NIAID NIH HHS/United States
- R03 DK100709/DK/NIDDK NIH HHS/United States
- R01 AG043608/AG/NIA NIH HHS/United States
- P30 AG021342/AG/NIA NIH HHS/United States
- K08 DK082618/DK/NIDDK NIH HHS/United States
- T32 AI055403/AI/NIAID NIH HHS/United States
- UL1 TR000142/TR/NCATS NIH HHS/United States
- DP3 DK112227/DK/NIDDK NIH HHS/United States
- R56 AI105097/AI/NIAID NIH HHS/United States
- UL1 RR024139/RR/NCRR NIH HHS/United States
- K24 AG042489/AG/NIA NIH HHS/United States
- U19 AI089992/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
